Versartis, Inc. (VSAR) Director Srinivas Akkaraju Acquires 513,872 Shares of Stock

Versartis, Inc. (NASDAQ:VSAR) Director Srinivas Akkaraju bought 513,872 shares of the stock in a transaction on Monday, December 4th. The stock was purchased at an average price of $2.21 per share, for a total transaction of $1,135,657.12. Following the completion of the purchase, the director now directly owns 14,955 shares in the company, valued at $33,050.55. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Srinivas Akkaraju also recently made the following trade(s):

  • On Friday, December 1st, Srinivas Akkaraju bought 419,700 shares of Versartis stock. The stock was purchased at an average price of $2.13 per share, for a total transaction of $893,961.00.

Shares of Versartis, Inc. (VSAR) remained flat at $$2.02 during trading hours on Wednesday. The company’s stock had a trading volume of 909,500 shares, compared to its average volume of 814,079. Versartis, Inc. has a 1-year low of $1.60 and a 1-year high of $24.00. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.52 and a quick ratio of 1.52.

Versartis (NASDAQ:VSAR) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported ($1.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.78). During the same period in the prior year, the firm posted ($0.92) EPS. analysts forecast that Versartis, Inc. will post -4.14 earnings per share for the current year.

Several analysts have recently weighed in on VSAR shares. Morgan Stanley restated an “equal weight” rating and set a $4.00 price objective (up previously from $3.00) on shares of Versartis in a research report on Friday, September 22nd. Cantor Fitzgerald restated an “overweight” rating and set a $14.00 price objective (down previously from $34.00) on shares of Versartis in a research report on Friday, September 22nd. Piper Jaffray Companies restated a “buy” rating and set a $26.00 price objective on shares of Versartis in a research report on Friday, September 8th. Cowen cut shares of Versartis from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $45.00 to $3.00 in a research report on Friday, September 22nd. Finally, Bank of America cut shares of Versartis from a “buy” rating to a “neutral” rating in a research report on Monday, September 25th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and three have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $7.22.

Large investors have recently modified their holdings of the stock. Bank of America Corp DE raised its position in Versartis by 46.3% in the 1st quarter. Bank of America Corp DE now owns 9,482 shares of the biopharmaceutical company’s stock worth $203,000 after purchasing an additional 3,001 shares during the period. Tudor Investment Corp ET AL purchased a new position in Versartis in the 2nd quarter worth $218,000. Numeric Investors LLC purchased a new position in Versartis in the 2nd quarter worth $246,000. Voya Investment Management LLC raised its position in Versartis by 26.1% in the 2nd quarter. Voya Investment Management LLC now owns 14,960 shares of the biopharmaceutical company’s stock worth $261,000 after purchasing an additional 3,094 shares during the period. Finally, State of Wisconsin Investment Board purchased a new position in Versartis in the 2nd quarter worth $419,000. Institutional investors own 49.18% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at https://www.com-unik.info/2017/12/06/versartis-inc-vsar-director-srinivas-akkaraju-acquires-513872-shares-of-stock.html.

About Versartis

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.

Insider Buying and Selling by Quarter for Versartis (NASDAQ:VSAR)

What are top analysts saying about Versartis Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Versartis Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit